HIGHLIGHTS
- who: Justine Habault and collaborators from the INSERM , Team, Onco-Dermatology and Therapies, Paris, France have published the paper: Validation of AAC-11-Derived Peptide Anti-Tumor Activity in a Single Graft Su00e9zary Patient-Derived Xenograft Mouse Model, in the Journal: Cells 2022, 11, 2933. of /2022/
- what: Using this model the authors evaluated the therapeutic potential of RT39 a cell-penetrating peptide derived from the survival protein anti-apoptosis clone 11 (AAC-11) that the authors previously characterized as specifically inducing apoptosis of Su00e9zary patients` malignant clone ex vivo. The study was approved by . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.